TY - JOUR T1 - Superior anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study JF - medRxiv DO - 10.1101/2020.06.26.20140699 SP - 2020.06.26.20140699 AU - Frederic Arnold AU - Lukas Westermann AU - Siegbert Rieg AU - Elke Neumann-Haefelin AU - Paul Biever AU - Gerd Walz AU - Johannes Kalbhenn AU - Yakup Tanriver Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/01/2020.06.26.20140699.abstract N2 - Background Coronavirus disease 2019 (COVID-19) patients who are admitted to intensive care units (ICU) have a high risk of requiring renal replacement therapy (RRT) due to acute kidney injury (AKI). Concomitantly, COVID-19 patients exhibit a state of hypercoagulability that can affect circuit lifespan. An optimal anticoagulation strategy is therefore needed in order to maintain circuit patency and therapeutic efficiency of RRT.Methods Retrospective single-centre cohort study on 71 critically ill COVID-19 patients at the University of Freiburg Medical Center. Included were all patients aged 18 years and older with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that were admitted to ICU between February 26 and May 21, 2020. We collected data on the COVID-19 disease course, AKI, RRT, thromboembolic events and anticoagulation. Primary outcome of the study was the effect of different anticoagulation strategies during RRT on extracorporeal circuit lifespans.Results Anticoagulation during continuous veno-venous haemodialysis (CVVHD) was performed with unfractionated heparin (UFH) or citrate. Mean treatment time in the UFH group was 21.3h (SEM: ±5.6h). Mean treatment time in the citrate group was 45.6h (SEM: ±2.7h). Citrate anticoagulation prolonged treatment duration significantly by 24.4h (p=0.0014). Anticoagulation during sustained low-efficiency daily dialysis (SLEDD) was performed with UFH, argatroban or low molecular weight heparin (LMWH). Mean dialysis time with UFH was 8.1h (SEM: ±1.3h), argatroban 8.0h (SEM: ±0.9h) and LMWH 11.8h (SEM: ±0.5h). Compared to UFH and argatroban, LMWH significantly prolonged treatment times by 3.7h (p=0.0082) and 3.8h (p=0.0024), respectively.Conclusions UFH fails to prevent early clotting events in dialysis circuits. For patients, who do not require an effective systemic anticoagulation, regional citrate dialysis is the most effective strategy in our cohort. For patients, who require an effective systemic anticoagulation treatment, the usage of LMWH results in the longest circuit life spans.Funding Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Germany. Else Kröner-Fresenius-Stiftung, Bad Homburg, Germany. Deutsche Forschungsgemeinschaft, Bonn, Germany.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFA is supported by the Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg. LW is supported by the Else Kroener-Fresenius-Stiftung (2016_Kolleg.03), Bad Homburg, Germany. ENH is supported by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. YT is supported by the Else Kroener-Fresenius-Stiftung (2017_EKES.34), Bad Homburg, Germany and the Deutsche Forschungsgemeinschaft (SFB 1160 (P06/ B08)), Bonn, Germany.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analysis and publication of the data was approved by the local ethics committee (155/20 to SR and 1016/20 to JK, Chairman Prof. R. Korinthenberg).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors had full access to the patient records, and take responsibility for the accuracy and integrity of the data. ER -